New legislation to fight against falsified medicines adopted by EU

31 May 2011

The European Union Council on Friday formally adopted new legislation aimed at protecting patients against the rising threat of falsified medicines. The new EU law is a major step forward in fighting falsified medicines in the region, the Council stated.

It introduces new harmonized, pan-European safety and control measures. It will introduce in particular for medicines exposed to the risk of falsification a new safety feature unique for each package. This will facilitate identifying falsified medicines before they are handed out to patients.

The Directive also introduces a common logo for legally operating on-line pharmacies. Once implemented, it would make it easier for patients throughout the EU to distinguish between legal and illegal on-line pharmacies. It will also tighten the control of the complex distribution chain of medicines by introducing strengthened requirements for EU and non-EU manufacturers of active substances as well as for wholesale distributors of medicinal products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical